SBRT Combined with Camrelizumab and Apatinib for Conversion Therapy in Patients with Unresectable Hepatocellular Carcinoma.
•Stereotactic Body Radiotherapy Combined with Camrelizumab and Apatinib As Conversion Therapy Versus Camrelizumab Combined with Apatinib As First-Line Therapy for Unresectable Hepatocellular Carcinoma: a Prospective, Multicenter, Open-label, Randomized Controlled Clinical Trial.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
Study Contact
- Name: Ming Kuang
- Phone Number: +86-020-87755766
- Email: kuangm@mail.sysu.edu.cn
Study Contact Backup
- Name: Lixia Xu
- Phone Number: +86-020-87755766
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China, 510080
- The First Affiliated Hospital of Sun Yat-sen University
-
Contact:
- Ming Kuang
- Phone Number: +86-020-87755766
- Email: kuangm@mail.sysu.edu
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Signed Informed Consent Form (ICF).
- Aged 18 years or older.
- Hepatocellular carcinoma confirmed by histology/cytology. Cirrhosis meets the clinical diagnostic criteria for hepatocellular carcinoma of the American Association for the Diagnosis of Liver Diseases (AASLD).
- Barcelona Clinic Liver Cancer stage B or C disease, which was not amenable to radical surgery.
- ECOG Performance Status of 0 or 1.
- Child-Pugh class of A.
Exclusion Criteria:
- Known hepatocholangiocarcinoma, sarcomatoid HCC, mixed cell carcinoma and lamellar cell carcinoma; other active malignant tumor except HCC within 5 years or simultaneously.
- Existence of active autoimmune disease or history of autoimmune disease and may relapse.
- Patients with innate or acquired immune deficiency (e.g., HIV infection).
- Known allergies to study drugs or excipients.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: control group
|
Subjects receive Camrelizumab intravenously.
Subjects receive Apatinib orally.
|
|
Experimental: Experimental group
|
Subjects receive Stereotactic Body Radiotherapy combined with Camrelizumab and Apatinib as conversion therapy.
Subjects receive Camrelizumab intravenously.
Subjects receive Apatinib orally.
If subjects suitable for hepatic resection after conversion therapy, radical surgery and postoperative adjuvant therapy will be performed.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Overall Survival
Time Frame: Up to approximately 3 years
|
The primary endpoint of phase 3 study is OS
|
Up to approximately 3 years
|
|
The R0 Resection rate of the experimental group
Time Frame: Up to approximately 30 days
|
The primary endpoint of phase 2 study is the R0 Resection rate of the experimental group
|
Up to approximately 30 days
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Objective Response Rate (ORR)
Time Frame: Up to approximately 3 years
|
The ORR is assessed by the investigators according to RECIST v1.1 and mRECIST, respectively.
|
Up to approximately 3 years
|
|
Disease control rate (DCR)
Time Frame: Up to approximately 3 years.
|
The DCR is assessed by the investigators according to RECIST v1.1 and mRECIST, respectively.
|
Up to approximately 3 years.
|
|
Time to Response (TTR)
Time Frame: Up to approximately 3 years.
|
The TTR is assessed by the investigators according to RECIST v1.1 and mRECIST, respectively.
|
Up to approximately 3 years.
|
|
Duration of response (DoR)
Time Frame: Up to approximately 3 years.
|
The DoR is assessed by the investigators according to RECIST v1.1 and mRECIST, respectively.
|
Up to approximately 3 years.
|
|
Time to progression (TTP)
Time Frame: Up to approximately 3 years.
|
The TTP is assessed by The investigators according to RECIST v1.1 and mRECIST,
|
Up to approximately 3 years.
|
|
Event free survival (EFS)
Time Frame: Up to approximately 3 years.
|
The EFS is assessed by the investigators according to RECIST v1.1 and mRECIST, respectively.
|
Up to approximately 3 years.
|
|
Conversion rate
Time Frame: Up to approximately 30 days.
|
The conversion rate of the experimental group.
|
Up to approximately 30 days.
|
|
Resection rate
Time Frame: Up to approximately 30 days.
|
The resection rate of the experimental group.
|
Up to approximately 30 days.
|
|
R0 resection rate
Time Frame: Up to approximately 30 days.
|
The R0 resection rate of the experimental group.
|
Up to approximately 30 days.
|
|
Pathologic complete response (pCR) rate
Time Frame: Up to approximately 30 days.
|
The pCR rate of the experimental group.
|
Up to approximately 30 days.
|
|
Major pathological response (MPR)
Time Frame: Up to approximately 30 days.
|
The MPR rate of the experimental group.
|
Up to approximately 30 days.
|
|
Safety
Time Frame: Up to approximately 90 days.
|
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
|
Up to approximately 90 days.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MA-HCC-II/III-030
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.